University of Southampton researchers have identified a distinct subtype of diffuse large B‑cell lymphoma (DLBCL), termed “Mann-type DLBCL,” marked by a unique mannose sugar on the B‑cell receptor that fuels tumor survival and growth. According to News Medical Life Sciences, the discovery, detailed in Blood with collaborators from Canada and the United States, could enable more precise diagnosis and spur targeted therapies for patients who fare poorly on standard treatment.
Analyzing data from 595 DLBCL cases across two cohorts (BCCA de novo DLBCL and NCI DLBCL), the team detected mannose on the B‑cell receptor in roughly one-third of tumors and found that Mann-type DLBCL consistently carries this sugar. Because mannose is common on pathogens but not abundant on normal human cells, its presence on lymphoma cells appears to confer a selective advantage—driving faster proliferation, resistance to conventional anti-cancer drugs, and worse outcomes.
Lead investigator Prof. Francesco Forconi emphasized that recognizing Mann-type DLBCL as a high-risk category is crucial for tailoring care, as these patients do not respond well to standard regimens. The subtype can be identified using conventional laboratory assays, giving clinicians a pragmatic way to stratify risk and prioritize alternative strategies earlier in the treatment pathway.
The findings spotlight glycobiology as a decisive factor in cancer behavior. “Finding mannose structures driving tumour growth is remarkable,” said co-author Prof. Max Crispin, noting how the integration of molecular insight and clinical datasets transformed understanding of this disease.
Clinically, the work opens several paths: leveraging mannose as a diagnostic biomarker; designing therapies that block mannose–receptor interactions or target mannose-decorated cells; and rethinking frontline choices for patients flagged as Mann-type. By defining this sugar-dependent biology, the study lays the groundwork for more effective, personalized treatments and offers new hope to a sizable subset of DLBCL patients who urgently need better options.
